ALKS 4230 is an experimental immunotherapy drug which works by targetting a molecule called IL-2. This allows the body to send more signals to the immune system, calling for greater numbers of immune cells to come and destroy any cancerous cells.
The other drug used in this study is called Pembrolizumab (Keytruda®). It is already approved for the treatment of kidney cancer when used in combination with another drug, called Axitinib (INLYTA®).
This study will investigate the safety and effectiveness of ALKS 4230 alone, or in combination with Pembrolizumab. As such, you may be assigned to one of two treatment groups:
- ALKS 4230 alone
- ALKS 4230 with Pembrolizumab
In order to maximize effectiveness and minimize side effects, difference doses of each drug may be used to determine the optimal dosage of these medications.
- All subtypes eligible
- Advanced kidney cancer that cannot be removed by surgery
- No further drug treatments are available or recommended
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreAlkermes Investigational Site||Principal Investigator||LocationEdmonton, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreAlkermes Investigational Site||Principal Investigator||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreAlkermes Investigational Site||Principal Investigator||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreAlkermes Investigational Site||Principal Investigator||LocationQuebec City, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreAlkermes Investigational Site||Principal Investigator||LocationMontreal, QC||Trial StatusRecruiting|